Literature DB >> 28041328

Image-guided stereotactic radiosurgery for treatment of spinal hemangioblastoma.

James Pan1, Allen L Ho1, Myreille D'Astous1, Eric S Sussman1, Patricia A Thompson1, Armine T Tayag1, Louisa Pangilinan1, Scott G Soltys2, Iris C Gibbs2, Steven D Chang1.   

Abstract

OBJECTIVE Stereotactic radiosurgery (SRS) has been an attractive treatment option for hemangioblastomas, especially for lesions that are surgically inaccessible and in patients with von Hippel-Lindau (VHL) disease and multiple lesions. Although there has been a multitude of studies examining the utility of SRS in intracranial hemangioblastomas, SRS has only recently been used for spinal hemangioblastomas due to technical limitations. The purpose of this study is to provide a long-term evaluation of the effectiveness of image-guided radiosurgery in halting tumor progression and providing symptomatic relief for spinal hemangioblastomas. METHODS Between 2001 and 2011, 46 spinal hemangioblastomas in 28 patients were treated using the CyberKnife image-guided radiosurgery system at the authors' institution. Fourteen of these patients also had VHL disease. The median age at treatment was 43.5 years (range 19-85 years). The mean prescription radiation dose to the tumor periphery was 21.6 Gy (range 15-35 Gy). The median tumor volume was 0.264 cm3 (range 0.025-70.9 cm3). Tumor response was evaluated on serial, contrast-enhanced CT and MR images. Clinical response was evaluated by clinical and imaging evaluation. RESULTS The mean follow-up for the cohort was 54.3 months. Radiographic follow-up was available for 19 patients with 34 tumors; 32 (94.1%) tumors were radiographically stable or displayed signs of regression. Actuarial control rates at 1, 3, and 5 years were 96.1%, 92.3%, and 92.3%, respectively. Clinical evaluation on follow-up was available for 13 patients with 16 tumors; 13 (81.2%) tumors in 10 patients had symptomatic improvement. No patient developed any complications related to radiosurgery. CONCLUSIONS Image-guided SRS is safe and effective for the primary treatment of spinal hemangioblastomas and is an attractive alternative to resection, especially for those with VHL disease.

Entities:  

Keywords:  ARE = adverse radiation event; CyberKnife; Dmax = maximum point dose; LINAC = linear accelerator; SRS = stereotactic radiosurgery; VHL = von Hippel-Lindau; hemangioblastoma; stereotactic radiosurgery; von Hippel-Lindau

Mesh:

Year:  2017        PMID: 28041328     DOI: 10.3171/2016.10.FOCUS16361

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  5 in total

Review 1.  Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Authors:  Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

2.  Stereotactic radiosurgery for central nervous system hemangioblastoma: systematic review and meta-analysis.

Authors:  James Pan; Rashad Jabarkheel; Yuhao Huang; Allen Ho; Steven D Chang
Journal:  J Neurooncol       Date:  2017-12-04       Impact factor: 4.130

3.  Stereotactic radiotherapy for spinal hemangioblastoma - disease control and volume analysis in long-term follow up.

Authors:  Jakub Cvek; Lukas Knybel; Stefan Reguli; Radim Lipina; Pavla Hanzlikova; Petr Šilhán; Kamila Resova; Tomas Blazek; Martin Palicka; David Feltl
Journal:  Rep Pract Oncol Radiother       Date:  2022-03-22

Review 4.  Management Strategies and Outcomes for VHL-related Craniospinal Hemangioblastomas.

Authors:  Christ Ordookhanian; Paul E Kaloostian; Samer S Ghostine; Philippe E Spiess; Arnold B Etame
Journal:  J Kidney Cancer VHL       Date:  2017-08-28

5.  Combined Microsurgery and Radiotherapy for Multiple Spinal Cord Hemangioblastomas with Holocord Syrinx in von Hippel-Lindau Disease: A Case Report.

Authors:  Nicolas Knoop; Clemens Seidel; Clara Frydrychowicz; Jürgen Meixensberger
Journal:  J Neurol Surg Rep       Date:  2019-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.